Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Injectable Cardiac Stimulator Corrects Heart Arrhythmia in Emergency Situations

By HospiMedica International staff writers
Posted on 29 Aug 2024

Arrhythmia, a condition characterized by irregular heartbeats, occurs when the heart's electrical signals are disrupted, causing it to beat too quickly, slowly, or unevenly. More...

While medications are commonly used to manage arrhythmia, some procedures can directly alter the heart's rhythm, such as the use of defibrillators or the surgical implantation of pacemakers. However, such interventions can be particularly challenging to implement in remote or conflict areas where access to such medical devices is limited. Now, research on animals has demonstrated a groundbreaking approach: the injection of a nanoparticle solution around the heart that forms a temporary, self-assembling heart stimulator. This device can correct arrhythmias in emergencies through an external power source and then naturally disintegrates after its use, as detailed in a publication in Nature Communications.

Nanoparticles are minuscule, allowing them to be administered via an ultra-thin needle. In a collaborative effort led by researchers at Lund University (Lund, Sweden), these nanoparticles were shown to form a conductive polymer structure around the heart upon contact with tissue. This structure seamlessly integrates with cardiac cells, supports ECG monitoring, regulates heartbeat, and corrects arrhythmic events. The close contact between the polymer and heart tissue ensures that the stimulator functions efficiently with minimal power, which can be supplied by portable devices such as a mobile phone. By connecting a cable from the phone to the injection site near the heart, the phone can power the electrode.

The research team plans to develop a mobile app that would allow individuals to control the arrhythmia until professional medical help can be accessed. Initial tests have been conducted on small animal models like zebrafish and chicken embryos, adhering to the 3R principle to minimize the use of mammalian subjects in scientific research. With promising results from these preliminary stages, the researchers aim to advance to testing on larger animals, such as pigs, to pave the way for potential human application.

"We have developed an injectable heart stimulator for emergency situations, which consists of a syringe loaded with a solution of nanoparticles," said Roger Olsson, Professor of Chemical Biology and Therapeutics at Lund University and Professor of Medicinal Chemistry at the University of Gothenburg.

"The method is minimally invasive. Moreover, the heart stimulator spontaneously degrades and is excreted from the body after treatment, so it does not need to be surgically removed," added Martin Hjort, Associate Researcher in Chemical Biology and Therapeutics at Lund University.

Related Links:
Lund University


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.